Handelsbanken Fonder Ab Arcellx, Inc. Transaction History
Handelsbanken Fonder Ab
- $24.3 Billion
- Q1 2025
A detailed history of Handelsbanken Fonder Ab transactions in Arcellx, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 11,600 shares of ACLX stock, worth $719,432. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,600
Previous 11,600
-0.0%
Holding current value
$719,432
Previous $890,000
14.49%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
44.7MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$271 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$232 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$218 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$216 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$207 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.72B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...